This document is a Corrigendum for the article "Engineered biosynthesis of plant polyketides by type III polyketide synthases in microorganisms," originally published in Frontiers in Bioengineering and Biotechnology.
Because this is a correction notice rather than a primary research paper, the summary below focuses on the scientific content clarified by the corrected figures and the metabolic engineering context they provide.
TL;DR
This corrigendum fixes a clerical error in a major review of microbial "bio-factories." It restores the correct captions to three vital pathway maps that illustrate how researchers engineer E. coli and yeast to produce high-value plant compounds like resveratrol and naringenin.
What Problem Does This Paper Address?
Plants produce a vast array of polyketides—complex molecules with pharmaceutical and nutritional value (e.g., antioxidants and anti-inflammatories). However, extracting these from plants is often inefficient, resource-heavy, and yields very little product.
The original research addresses the challenge of metabolic engineering: transplanting the "machinery" (Type III Polyketide Synthases or PKSs) from plants into fast-growing microorganisms like E. coli and S. cerevisiae. The specific problem addressed by this corrigendum was a mismatch between the figures and their descriptions, which could lead to confusion for researchers trying to replicate these metabolic "blueprints."
Methods
The paper reviews and illustrates two primary strategies for microbial production:
- Heterologous Pathway Reconstruction: Inserting plant-derived genes (like PAL, C4H, and 4CL) into a microbial host to create a functional assembly line for plant chemicals.
- Precursor Enhancement Engineering: Modifying the host's internal metabolism to increase the supply of "starter" molecules. For polyketides, this usually means boosting levels of Malonyl-CoA and aromatic amino acids (L-Phe and L-Tyr).
The corrected figures specifically detail the genetic "knobs" researchers turn—such as overexpressing certain enzymes (indicated in red in the figures) or deleting competing pathways (indicated in blue)—to maximize yield.
Datasets
Not discussed in the paper. As a review and correction of metabolic pathways, it does not introduce new experimental datasets or benchmarks.
Key Insights and Ideas
The corrected figures provide a high-level "cheat sheet" for metabolic engineers:
- The "Two-Branch" Strategy: To make polyketides, the cell needs two distinct streams of building blocks. Branch 1 typically provides the "extender" units (Malonyl-CoA), while Branch 2 provides the "starter" units (derived from the Shikimate pathway).
- Host-Specific Logic: The engineering requirements differ significantly between bacteria and yeast.
- In E. coli (Figure 2), the focus is often on overexpressing genes like
ppsAandtktAto drive carbon toward the Shikimate pathway. - In S. cerevisiae (Figure 3), researchers often target feedback-resistant versions of enzymes (like
ARO4andARO7) to prevent the cell from "shutting down" production once levels of the target amino acids rise. - Modular Tailoring: Once the core polyketide scaffold (like Naringenin) is built, "downstream tailoring" enzymes can be added to perform methylation, oxidation, or glycosylation, allowing for a "plug-and-play" approach to chemical diversity.
Key Results
The corrigendum ensures the accurate presentation of the metabolic maps for four major target compounds:
- Pinocembrin & Pinosylvin: Derived from L-phenylalanine.
- Naringenin & Resveratrol: Derived from L-tyrosine.
The figures clarify that while the core PKS enzymes (like CHS or STS) are the "stars" of the show, the supporting cast of metabolic tweaks (precursor enhancement) is what actually makes industrial-scale production viable.
Limitations and Future Work
Not discussed in the paper. As a corrigendum, the scope is limited to correcting the published record regarding the figure-caption mismatch.
Summary updated